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1. Introduction 
Pain is a complex disease. The complexities and co-morbidities of this disease include 
depression, anxiety, addiction, and other psychological diagnoses that lead to difficulties in 
management and aberrant behavior such as not taking medications as prescribed, taking 
additional medications, or illicit drugs. In the effort to provide the highest standard of care 
for their patients, pain physicians are required to continually assess patients for addiction 
and, if necessary, refer them to addictionologists for additional treatment (Chou et al., 2009). 
1.1 Chronic opioid therapy 
In this chapter we will refer to pain patients as those persons being treated with chronic 
opioid therapy for non-cancer-related pain. It is this patient population that has been 
associated with opiate abuse and diversion, and therefore monitoring these patients for 
drug use in a manner analogous to therapeutic drug monitoring is necessary. One of the 
most frequent complaints by patients seeing pain physicians is back pain, which is often 
associated with failed back surgery (Manchikanti et al., 2004; Michna et al., 2007).  Currently 
opiate medications are one of the treatments of choice used by physicians to provide pain 
relief. These medications can induce euphoria as well as pain relief; because of this, opiates 
are frequently abused by this population, as well as the general population (National Survey 
on Drug Use and Health: Detailed Tables - Prevalence Estimates, Standard Errors, P Values, 
and Sample Sizes, 1995-2006; Webster & Dove, 2007). Additionally, these medications are 
associated with physical as well as psychological dependence and can pose addiction risks 
(Webster & Dove, 2007). 
1.2 Pain treatment 
One of the treatments of choice for chronic pain involves strong medications such as 
opioids, as well as additional or adjuvant medications (Chou et al., 2009; Trescot et al., 2006). 
Side effects of opioids include sedation, dizziness, nausea, vomiting, and constipation. 
Living day to day with any or all of these symptoms is challenging at the least and is 
compounded by the underlying pain these patients suffer from. Naturally, patients often 
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attempt to minimize the side effects by taking less of the medication when side effects are 
particularly debilitating or unpleasant. “Chronic pain patients often adjust their dose of 
prescribed medication in response to changing levels of activity with no malicious or 
maladaptive intent. Although they may state that their pattern of use of medications is 
stable, this is often a statement made ‘‘on average’’ rather than a precise pattern of use. This 
is particularly evident with short-acting medications used in the treatment of breakthrough 
pain.” (Gourlay & Heit, 2010b)  
UDT is used to give confidence to both the physician and the patient that the patient is 
following the medication regimen and is therefore getting the most benefit from their 
treatment. In addition, the side effects of these medications often result in their misuse, 
underuse, and/or mixing of medications that are not prescribed (Manchikanti et al., 2004). 
This can also result in the social problems of abuse, misuse, or diversion of these 
medications. These factors require of pain physicians that they be particularly attentive to 
their prescribing practices.  Adding to the complexity of managing pain patients is the fact 
that these medications are controlled substances and cannot be purchased over the counter, 
and so have high street value (Katz et al., 2003; National Prescription Drug Threat 
Assesment, 2009). This in turn requires of the physician that he or she determine whether 
patients under their care are compliant with their medication regime, binging on their 
medications, or diverting them for financial gain (Manchikanti et al., 2005, 2006a, 2006b). 
1.3 Complications of pain treatment 
Further compounding the situation, alcohol use is of major concern to the physician because 
alcohol-drug interactions can cause morbidity (Harmful Interactions: Mixing Alcohol with 
Medicines, 2007). Although physicians prohibit patient alcohol use during treatment with 
opiates or benzodiazepines, verbal contracts are commonly broken and therefore alcohol use 
must be monitored with (UDT) to manage the high risk of alcohol-drug reactions and 
mortality (Chou et al., 2009; Trescot et al., 2006). In addition, for reasons involving 
inadequate pain control, sleep deprivation, and psychological pathology, this patient 
population commonly takes other medications not prescribed by treating physicians as well 
as illicit drugs (Manchikanti et al., 2005, 2006a, 2006b). To respond to these potential 
problems, physicians traditionally relied upon behavioral assessment and pill counts to aid 
them in making treatment decisions. UDT has augmented these tools by providing 
physicians with objective, scientifically measurable outcomes to help them make decisions 
(Gourlay et al., 2010; Hammett-Stabler & Webster, 2008; Nafziger & Bertino, 2009; Reisfield 
et al., 2007). A detailed protocol of how to appropriately prescribe these controlled 
substances for this population is discussed in the book Universal Precautions, by Gourlay and 
Heit (Gourlay et al., 2005). 
2. Urine drug testing 
Traditionally, UDT has been associated with forensic testing, often referred to as workplace 
testing, to detect illicit drug use in employees. Workplace UDT has traditionally focused on 
identifying use of abused drugs including amphetamines (methamphetamine), cocaine, 
marijuana, phencyclidine (PCP), and heroin (opiates) (Federal Register - Mandatory 
Guidelines and Proposed Revisions to Mandatory Guidelines for Federal Workplace Drug 
Testing Programs [Federal Register], 2004). This type of testing is oriented toward 
determining positive results; that is, identifying the presence of an illicit substance. The 
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reasoning behind this focus is obvious; a positive result for a prohibited substance is a  cause 
for a consequence such as job dismissal (Federal Register, 2004). Testing for these drugs 
usually follows scheduled guidelines established by the Substance Abuse and Mental 
Health Services Administration (SAMHSA) (Federal Register, 2004). Analytically, the testing 
involves qualitative immunoassay screening followed by confirmation by mass 
spectrometry. Testing for patients on chronic opioid therapy is a different paradigm as both 
positive and negative results are important. It also requires assays that are more sensitive 
and can determine both the parent drug and one or more of its metabolites.  
2.1 Immunoassays 
Immunoassays are tests that are based on the ability of an antibody to bind with a drug 
(Feldkamp, 2010). Antibodies are made in such a way that they bind with a specific drug, such 
as morphine. In one approach, manufacturers of point of care (POC) devices embed test strips 
with antibodies and install them in devices designed to interact with urine specimens 
(Amedica Drug Screen Test Cup). A urine specimen with the drug in it (in this example, 
morphine) will displace the drug-indicator molecule on the test strip causing the morphine 
drug indicator line to disappear or change color. These test strips are then visually inspected 
by the person administering the test. The absence or presence of a line or the change in color, 
such as on a home pregnancy test, indicates whether the result is positive or negative. The 
immunoassay antibody binding reaction can be measured in other, more sophisticated ways 
than using test strips, such as reference laboratory analytical instruments (Olympus Au640 
Product Information; Siemens V-Twin Analyzer Product Information; Thermo Fisher Mgc-240 
Analyzer Product Information). However, the fundamental property of immunoassays is 
always the binding reaction of the antibody to the test drug (analyte). 
2.2 Limitations of immunoassay 
The qualitative immunoassay model of testing is only a partial UDT solution for the pain 
population (Gourlay et al., 2010; Hammett-Stabler & Webster, 2008; Nafziger & Bertino, 
2009; Reisfield et al., 2007). There are a number of reasons for this. First, doctors treating 
patients for pain are concerned with negative as well as positive results. This is because a 
negative result can mean that a patient is not taking a prescribed medication. Second, 
workplace UDT assays do not fit the clinical medication regimen used in the treatment of 
pain patients and do not take into account the variable dosing often employed by pain 
patients as they try to balance their need for pain relief against the side effects of these 
medications (Gourlay & Heit, 2010a). In analytical terms this means that the cutoff for 
detection and quantitation (concentration of drug present) must be low enough to capture 
minimal use of the drug. Thirdly, the physicians need to have an exact indication of the 
medications the patients are taking. For example, a positive opiate test does not indicate 
whether the patient is on codeine, hydrocodone, morphine, or hydromorphone. That is, it 
measures the class not the particular drug. Each of these are specific medications the 
physician may choose to treat the patient with, so in order to establish compliance it is 
necessary to determine exactly which medication has been ingested and assure the patient is 
not taking additional opiates which could create an unsafe situation (Cone et al., 2008). 
Finally, if an immunoassay screening method is used, the antibody must detect all drugs of 
that particular class. Recent advances in designing opiate and benzodiazepine classes of 
drugs have resulted in agents which do not react well with the traditional antibodies. and  
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are used in much lower concentrations than the earlier-designed drugs (Fraser, 2001). This 
complicates identification of these new agents by immunoassay.  
3. Drugs observed in pain patients 
Table 1 lists both licit and illicit drugs as well as alcohol and the frequency observed in the 
pain patient population tested by Millennium Laboratories. These observations are similar 
to those reported by Cone (Cone et al., 2008). The medications most commonly found in the 
urine of this population are clearly hydrocodone and oxycodone, followed by morphine and 
hydromorphone; codeine is not frequently prescribed for this population. Benzodiazepines 
are the next most prescribed group. Other opioid medications such as fentanyl, meperidine, 
tramadol, and propoxyphene are less frequently used. Use of the muscle relaxants 
carisoprodol is commonly seen. Marijuana is by far the most prevalent among the illicit 
drugs, followed by cocaine and methamphetamine. From the table it is clear that alcohol use 
is about 10% as measured by the presence of alcohol’s metabolites ethyl glucuronide (EtG) 
and ethyl sulfate (EtS) (Crews et al., 2011a; Dahl et al., 2002; Helander & Beck, 2005; 
Helander et al., 1996; Schmitt et al., 1997; Stephanson et al., 2002; Wojcik & Hawthorne, 2007; 
Wurst et al., 2006; Wurst et al., 2004). These data show that in order to provide appropriate 
monitoring and decrease risk and mortality for this population, a broad test menu is needed. 
These same drugs are often abused and frequently found to be present though they had not 
been prescribed by the treating physician. Table 2 shows the frequency of these non-
prescribed drugs in the pain patient population.  
3.1 Need for urine drug testing 
Many physicians prescribing opioids for non-cancer pain patients follow guidelines 
established by the American Pain Society (Chou et al., 2009). These guidelines specify the 
regular or periodic use of UDT as a component of treatment, including administering UDT 
upon assessing potential risk for substance abuse, misuse or addiction (Atluri & Sudarshan, 
2003; Ives et al., 2006; Madras et al., 2009). Guidelines also suggest that doctors use UDT to 
monitor patient adherence to prescribed treatments and further state that periodic UDT is 
warranted because “the therapeutic benefits of these medications are not static and can be 
affected by changes in the underlying pain condition, coexisting disease, or in psychological 
or social circumstances” (Chou et al., 2009). In observation of these recommendations, many 
physicians use POC devices to obtain a real time, in-office assessment of patient compliance, 
illicit drug use and possible diversion (Manchikanti et al., 2006b, 2010). 
3.2 Point of care testing 
As mentioned previously, these POC devices are qualitative immunoassays that test for 
various drug classes as well as a few specific drugs. A typical POC device can measure 12 
drugs or drug classes (Amedica Drug Screen Test Cup). The most commonly monitored 
agents are barbiturates, benzodiazepines, opiates, oxycodone, propoxyphene, methadone, 
tricyclic antidepressants and the illicit drugs methamphetamine, marijuana, cocaine, 
methylenedioxymethamphetamine (MDMA), and phencyclidine (PCP). The physicians use 
these screens to immediately detect adherence to regimen or non-adherence to the 
prescribed drug therapy. At that point they can elicit a more complete drug history, initiate 
a conversation assessing the need for additional medications not prescribed, or confront the  
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N % Mean Median Range Cutoff
Positive Positive  (ng/mL)  (ng/mL)  (ng/mL)  (ng/mL)
Alcohol 10,594 10.0%
Ethyl Glucuronide 8,602 81.2% 59,827.9 7,220.1 500.47 - 5,942,830 500
Ethyl Sulfate 6,644 62.7% 18,660.7 3,546.1 500.17 - 1,565,150 500
Ethanol (Screen) 2,410 22.7% 735.1 mg/dL 68.6 mg/dL 20 - 151,316 mg/dL 20 mg/dL
Total Specimens Tested 106,014
Amphetamines 7,005 4.2%
Amphetamine 6,045 86.3% 8,471.2 2,790.2 100.31 - 409,816 100
Methamphetamine 1,178 16.8% 18,217.8 3,263.8 105.12 - 453,763 100
MDA 961 13.7% 1,771.1 844.5 101 - 416,68.9 100
MDMA 74 1.1% 5,328.2 1,260.6 120.14 - 40,395.3 100
Total Specimens Tested 167,533
Barbiturates 4,797 3.6%
Barbiturates (Screen) 4,797 100.0% 927.8 904.0 200 - 15,886 200
Total Specimens Tested 133,032
Benzodiazepines 60,160 35.6%
α-Hydroxyalprazolam 26,954 44.8% 479.9 177.3 20 - 55,249.1 20
Oxazepam 18,475 30.7% 2,036.0 617.4 40 - 203,128 40
7-Amino-Clonazepam 16,466 27.4% 674.6 287.0 20.01 - 47,501.7 20
Temazepam 15,647 26.0% 5,552.3 851.9 50 - 752,950 50
Nordiazepam 12,758 21.2% 693.9 281.5 40 - 25,864.3 40
Lorazepam 6,390 10.6% 1,583.1 681.2 40.09 - 63,170.8 40
Total Specimens Tested 168,980
Buprenorphine 6,308 6.0%
Buprenorphine 5,841 92.6% 313.0 75.1 10.01 - 58,691.5 10
Norbuprenorphine 4,237 67.2% 639.8 279.0 20 - 13,615.1 20
Total Specimens Tested 104,972
Cannabinoids 11,752 11.3%
cTHC 11,752 100.0% 579.6 153.1 15 - 25,960.3 15
Total Specimens Tested 104,453
Carisoprodol 13,302 16.4%
Meprobamate 13,188 99.1% 36,884.0 16,190.5 100.18 - 1,244,200 100
Carisoprodol 5,379 40.4% 2,931.9 455.0 100.1 - 648,442 100
Total Specimens Tested 80,990
Cocaine 4,951 3.0%
Cocaine metabolite 4,951 100.0% 12,372.5 627.1 50.05 - 342,160 50
Total Specimens Tested 166,501
Drug Class
 
Table 1. Drug and Metabolite Prevalence, Positivity, and Concentrations. N = 184,049 patient 
specimens. Test dates: 10/01/09–4/29/10. 
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N % Mean Median Range Cutoff
Positive Positive  (ng/mL)  (ng/mL)  (ng/mL)  (ng/mL)
Fentanyl 13,141 14.1%
Norfentanyl 11,589 88.2% 626.8 236.6 8 - 47,354.9 8
Fentanyl 9,283 70.6% 109.4 36.1 2 - 33,050.7 2
Total Specimens Tested 93,526
Meperidine 6,310 7.3%
Normeperidine 4,247 67.3% 1,456.3 339.5 50 - 276,993 50
Meperidine 2,522 40.0% 34,321.8 13,533.4 50.18 - 616,862 50
Total Specimens Tested 86,344
Methadone 12,415 11.0%
EDDP 12,109 97.5% 7,871.9 4,117.3 100.05 - 251,835 100
Methadone 11,792 95.0% 5,265.1 2,409.4 100.11 - 260,433 100
Total Specimens Tested 113,073
Opiates 116,683 64.6%
Hydrocodone 59,346 50.9% 2,564.4 859.9 50 - 477,876 50
Hydromorphone 51,205 43.9% 836.0 240.4 50 - 204,633 50
Oxymorphone 49,688 42.6% 5,760.2 1,298.6 50 - 1,512,220 50
Oxycodone 41,603 35.7% 11,207.3 2,124.5 50 - 5,947,380 50
Morphine 21,400 18.3% 29,611.8 9,600.3 50.06 - 1,995,940 50
Codeine 3,686 3.2% 4,752.0 828.4 50.01 - 233,036 50
6-Acetylmorphine 465 0.4% 1,108.8 275.7 10.01 - 24,069.1 10
Total Specimens Tested 180,487
Phencyclidine 23 0.02%
Phencyclidine 23 100.0% 539.4 87.5 10.89 - 3,718.53 10
Total Specimens Tested 104,137
Propoxyphene 6,397 4.8%
Norpropoxyphene 6,395 100.0% 5,524.3 2,026.9 100 - 167,037 100
Propoxyphene 2,780 43.5% 1,919.5 583.6 100 - 178,006 100
Total Specimens Tested 133,992
Tapentadol 277 0.4%
Tapentadol 277 100.0% 11,557.1 6,870.3 52.05 - 492,895 50
Total Specimens Tested 66,797
Tramadol 6,521 12.1%
Tramadol 6,521 100.0% 19,288.0 8,191.4 100 - 601,928 100
Total Specimens Tested 54,111
Drug Class
 
Table 1. (continued). Drug and Metabolite Prevalence, Positivity, and Concentrations. N = 
184,049 patient specimens. Test dates: 10/01/09–4/29/10. 
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DRUG CATEGORY OCCURRENCES % of TOTAL
Benzodiazepine 14,559 28.32%
Illicit Drugs 6,769 13.17%
Natural and Semi-Synthetic Opioids 13,241 25.75%
Other 11,514 22.39%
Stimulants 954 1.86%
Synthetic Opioids 4,379 8.52%
TOTALS 51,416 100.00%
Total Creatinine Tests 69,888
Total RADAR C Positives 51,416
% POSITIVE 73.57%
Benzodiazepine 14,559
7-Amino-Clonazepam 3,864
Alpha-Hydroxyalprazolam 5,543
Lorazepam 1,079
Nordiazepam 1,907
Oxazepam 1,803
Temazepam 363
Illicit Drugs 6,769
6-MAM (Heroin metabolite) 165
Cocaine metabolite 1,710
Methamphetamine 320
MDMA 17
cTHC (Marijuana metabolite) 4,546
Phencyclidine 11
Natural and Semi-Synthetic Opioids 13,241
Buprenorphine 809
Codeine 692
Hydrocodone 5,138
Hydromorphone 1,789
Morphine 1,317
Norbuprenorphine 73
Oxycodone 2,618
Oxymorphone 805
Other 11,514
Carisoprodol 735
Ethyl Glucuronide 5,320
Ethyl Sulfate 4,820
Meprobamate 639
Stimulants 954
Amphetamine 954
Synthetic Opioids 4,379
EDDP (Methadone metabolite) 1,381
Fentanyl 729
Meperidine 29
Methadone 271
Norfentanyl 204
Normeperidine 55
Norpropoxyphene 898
Propoxyphene 25
Tapentadol 17
Tramadol 770
Table 2. Incidence of Non-prescribed Use of Prescription Medications and Illicit Drugs. 
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patient about illicit drug use. Point of care devices are extremely useful because they 
provide physicians with immediate information, particularly on initial patient intake. Of 
course, like many CLIA-waived (or simple) test devices, they do have limitations, inasmuch 
as they require that a person visually inspect them in order to interpret the results. For this 
reason as well as the fact that these units are not 100% accurate, manufacturers of POC 
devices recommend that doctors not confront patients without first confirming the POC 
results (Table 3) (Amedica Drug Screen Test Cup). Table 3 lists a number of known drugs or 
agents that cause false positive results in POC immunoassays. In contrast with POC 
immunoassay tests, which only show a positive or negative result, laboratory-based 
immunoassays are often semi-quantitative (Feldkamp, 2010). This means that a positive 
result for morphine will also indicate approximately how much morphine is in the 
specimen. These immunoassays have quality control and proficiency testing surveys that 
make the results more objective and reliable than those obtained using POC devices 
(American Proficiency Institute 2011 Catalog of Programs, 2011; College of American 
Pathologists 2011 Surveys and Anatomic Pathology Education Programs, 2011).  
 
POCT Kit 
Abbreviation 
Drug or Drug 
Class 
Target  Drugs1 
Compounds That May 
Cause A False Positive1 
THC Marijuana 
Marijuana and Marinol 
(contains THC), 
Prilosec, Protonix , 
efavirenz, NSAIDs 
COC Cocaine Cocaine Unknown/Infrequent 
OPI3002 Opiates 
Codeine, morphine, 
hydrocodone, 
hydromorphone. Also, poppy 
seeds that contain morphine. 
Oxycodone 
AMP 
Ampheta-
mines 
Amphetamine, Adderall. 
Occasionally:  benzphetamine, 
selegiline, Vicks Nasal Inhaler4
Phenylpropanolamine, 
ephedrine, 
pseudoephedrine, 
ranitidine,  
phentermine 
MET 
Methampheta-
mine 
Methamphetamine. 
Occasionally: benzphetamine, 
selegilene, Vicks Nasal 
Inhaler4 
Adderal, 
phenylpropanolamine, 
ephedrine,  
pseudoephedrine, 
ranitidine, phentermine 
PCP Phencyclidine Phencyclidine 
Venlafaxine, 
dextromethorphan, 
diphenhydramine 
MDMA 
Methylene-
dioxymetham
phetamine 
Methylenedioxy-
methamphetamine 
Phenylpropanolamine, 
ephedrine, 
pseudoephedrine, 
ranitidine, phentermine 
BAR Barbiturates 
Butalbital, phenobarbital, 
secobarbital, amobarbital and 
other barbiturates 
Unknown/Infrequent 
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BZO 
Benzodiaze-
pines 
Oxazepam, nordiazepam, 
temazepam, alprazolam and 
other benzodiazepines to 
varying degrees 
Oxaprozin, sertaline 
MTD Methadone Methadone Verapamil, quetiapine 
TCA 
Tricyclic 
Antidepres-
sants 
Amitriptyline, nortriptyline, 
imipramine, desipramine, 
doxepin and other tricyclics to 
varying degrees. 
Cyclobenzaprine, 
carbamazepine, 
diphenhydramine 
OXY3 Oxycodone Oxycodone and oxymorphone
Codeine, morphine, 
hydrocodone and 
hydromorphone 
Table 3. False Positive Results: Immunoassay Cross Reactants. 
1 While most immunoassays are highly selective for their target compounds, cross reactive compounds 
and adulterants, particularly when present at high concentrations may result in a false positive.  
Additional cross reactants have been reported and cross reactivity may vary between immunoassay 
manufacturers and lot to lot. The manufacturers of  point of care test devices recommend that positive 
results should be confirmed by mass spectrometry.  
2 OPI300 is an assay to detect codeine, morphine, hydrocodone and hydromorphone. Oxycodone may 
give a positive at higher concentrations. 
3 OXY is an assay to detect Oxycodone. Other opiates, esp. codeine, morphine, hydrocodone and 
hydromorphone may give a positive result at higher concentrations. 
4 Adderall contains amphetamine. Benzphetamine (Didrex) is metabolized to d-amphetamine and d-
methamphetamine. Selegiline (Eldepryl) is metabolized to l-amphetamine and l-methamphetamine. 
Vick’s Inhaler contains l-methamphetamine. 
3.3 Determining appropriate UDT cutoffs 
Sensitivity of detection currently used in many immunoassays may not be appropriate for 
the pain patient. This is because manufacturers set cutoffs for assays to identify overdose in 
emergency unit settings (Fraser & Zamecnik, 2003; Fraser, 2001; Hattab et al., 2000; Wingert, 
1997). There is a need to establish appropriate cutoffs for patients on clinical doses of their 
medications rather than the high concentrations encountered in overdose situations. 
Specifically, studies have been conducted that better identify the appropriate cutoff for the 
pain patient population (Pesce et al., 2011).  
One definition of appropriate cutoff levels is one that captures 97.5% or more of the 
population on a specific drug (Pesce et al., 2011). An example of the importance of setting 
appropriate cutoffs is for the drug clonazepam (West et al., 2010b). When measured by 
immunoassay using a nominal cutoff of 200 ng/mL, only 28% of the patients on the drug 
were determined to be compliant. When the same samples were measured by LC-MS/MS 
technique using a cutoff of 200 ng/mL, the group was found to be 70% compliant. Finally, 
when the LC-MS/MS cutoff was lowered to 40 ng/mL the group was 87% compliant. This 
study showed that first the immunoassay was insensitive in that the nominal 200 ng/mL 
cutoff did not apply to clonazepam, and second, a lower cutoff was needed to appropriately 
categorize compliance. Other studies have shown the need for lower cutoffs for pain 
medications (Mikel et al., 2009; Pesce et al., 2010a). As the consequences to the patient of 
dismissal from a practice can be very large and even life-changing (e.g., loss of insurance, 
loss of job or income), it is essential that physicians do not unjustifiably dismiss even a 
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single patient who is compliant with their medication regimens. This can be avoided by 
using appropriate cutoffs. 
In an attempt to better define appropriate cutoffs for the pain patient population, the 
quantitative urine drug test results were examined for the prescription medications listed in 
Table 4. Using the criterion that the cutoffs should capture 97.5% of the examined 
population and employing the LC-MS/MS cutoffs listed in Table 4 showed it was possible 
to meet this standard (Pesce et al., 2011). One limitation of this approach is that the time 
after last dose and the dose itself were not known for these subjects. Regardless of the 
limitations of the study, the lower cutoffs provide results that can clearly identify 
compliance more accurately than other methods. 
 
Estimated New 
Cutoff (Raw, ng/mL)
CR Normalized Cutoff 
(µg/g creatinine)
 7-Amino-Clonazepam 10 19 15
 Alpha-Hydroxyalprazolam 10 15 11
 Amphetamine 50 76 59
 Buprenorphine 5 7 5
 Carisoprodol 50 56 35
 Codeine 25 29 15
 Fentanyl 1 2 2
 Hydrocodone 25 41 31
 Hydromorphone 25 34 26
 Lorazepam 20 30 25
 Meperidine 25 88 28
 Meprobamate 50 92 113
 Methadone 50 89 74
 Morphine 25 59 52
 Oxycodone 25 45 46
 Oxymorphone 25 44 38
 Propoxyphene 50 60 42
 Tapentadol 25 42 58
 Tramadol 50 147 70
Drug
 Analytical 
Cutoff (ng/mL)
Lower 2.5%
 
Table 4. Medication Cutoff Values. Modified with permission from Pesce et al., 2011. 
As stated earlier, illicit drug use is common in this population (Madras et al., 2009; 
Schuckman et al., 2008). It stands to reason that identifying the appropriate illicit drug 
cutoffs for UDT is equally important. Using the same criterion as stated above, cutoffs for 
marijuana, cocaine, and methamphetamine have also been determined (Table 5) (West et al., 
2011a). The lowering of these illicit drug cutoffs consistent with the latest SAMHSA 
guidelines in which the cocaine and amphetamine cutoffs were lowered to capture more 
illicit drug users (Federal Register, 2004). 
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Raw 
(ng/mL)
CR Normalized 
(ng/mg CR)
Cocaine 29.6 17
Marijuana 9.5 6.2
Methamphetamine 56.1 33.5
Lower 2.5%
Drug
 
Table 5. Illicit Drug Cutoff Values. Modified with permission from West et al., 2011a. 
3.4 Confirmatory testing: mass spectrometry 
Physicians dealing with pain patients  not following the treatment plan or using illicit or 
non-prescribed medications, have difficulty with these situations (Jung & Reidenberg, 2007). 
The doctor must be absolutely confident that the test data from both the POC and laboratory 
conducting further testing is correct. By having positive results obtained in their offices as 
well as confirmatory laboratory data, physicians can confidently discuss expectations and 
behavioral changes with patients. Questions about laboratory mix-up of specimens or 
laboratory error can be dismissed.  
Many laboratories performing UDT on the pain patient population typically test specimens 
by immunoassay and then follow this with confirmation by mass spectrometry (Cone et al., 
2008). Mass spectrometry is an analytical technique that separates molecules based on their 
weight (mass) and fragmentation pattern. Identification is based on the fact that each drug 
has a specific mass and breakdown in the same way that each person has a specific 
fingerprint. A mass spectrometry instrument is usually coupled to a chromatographic 
column, in which the test drug, for example morphine, is separated from other components 
in the urine before submitting the sample into the mass spectrometer. The mass 
spectrometer identifies the test drug by its position in the chromatogram, the specific weight 
of the molecule, and by its fragmentation pattern. This technology is virtually foolproof. 
Mass spectrometry techniques are divided into two methods: gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Of the two, the newer LC-MS/MS is considered the gold standard, for reasons we 
will describe later (Siuzdak, 2006).  
In cases where the physician wants the results immediately (within hours), confirmatory 
mass-spectrometry methods used at the most modern diagnostic laboratories provide 
results within 24-30 hours. As stated above, the major limitations of immunoassays are 
inappropriate cutoffs (sensitivity), varying specificity for individual drugs, and cross-
reactivity with other agents producing both false-negative and false-positive results 
(Manchikanti et al., 2008). The term cross reactivity is used to describe the reaction of an 
antibody with a chemical that is not the original immunizing drug. The reaction is poor 
because the affinity is much worse than the original drug. By poor we mean that at the same 
concentration of the original drug the test compound does not bind as well. However, as the 
concentration of the test compound is increased it eventually saturates the antibody binding 
site giving a positive test result. 
3.5 Test menu requirement 
As mentioned earlier  a broader clinical laboratory UDT menu is necessary to accurately 
monitor the pain patient population. Smaller hospitals as well as physician offices cannot 
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meet this requirement. One reason for this is that immunoassays require separate 
analytical channels for each assay and this limits the number of tests a smaller laboratory 
may have in its menu (Olympus Au640 Product Information; Siemens V-Twin Analyzer 
Product Information; Thermo Fisher Mgc-240 Analyzer Product Information). Another 
reason is that certain drug tests may not exist for the laboratory’s specific instruments, 
and the addition of another instrument is financially prohibitive, particularly if that 
instrument is a mass spectrometer (Agilent Technologies, Inc.). Many physicians treating 
the pain patient population send specimens to reference laboratories specifically designed 
to provide the required test menu to meet these needs. Tests for new drugs (i.e., 
tapentadol) (Nucynta - Tapentadol, 2010) or new illicit substances (i.e., K2, spice) 
(Sobolevsky et al., 2010; Vardakou et al., 2010) encountered in the pain patient population 
can be rapidly set up and validated on LC-MS/MS instrumentation. Therefore, this 
analytical technique is supplementing screening by immunoassay. Because of the 
limitations of immunoassays, confirmatory testing is essential for accurate clinical 
assessment of medication usage. With confirmatory testing, physicians have specific 
evidence of what medications a patient is or isn’t taking. This assures the doctor that he or 
she is not discharging a patient inappropriately, and that care is appropriate and not 
limited.. The laboratories with the most advanced technology can eliminate the 
immunoassay step saving both the patient and the insurer money. 
3.6 Mass spectrometry as the gold standard for testing 
At this point in time, mass spectrometry is considered the method of choice for UDT 
analysis in pain management. This is because mass spectrometry offers the 
chromatographic separation and mass fragmentation patterns that are specific for the test 
medications such as opiates and benzodiazepines (Mohsin et al., 2007). In addition, this 
analytic approach uses isotope dilution to quantify the amount of drug in the urine 
specimen; isotope dilution is considered the gold standard for determining how much of a 
drug is in a specimen (quantitation) (Federal Register, 2004). This ability to quantify the 
amount of drug in urine has been proposed as a method of detecting drug abuse (Pesce et 
al., 2010c). However, it is important to note that it is not possible to relate the quantitative 
excretion of a drug to the drug dosage (Nafziger & Bertino, 2009). Quantitation of drugs 
using immunoassay technology is problematic, particularly if the antibody reagent cross 
reacts with multiple structurally related drugs; if the urine drug sample contains more 
than one drug in a class (i.e., hydrocodone and hydromorphone), the antibody reaction 
will vary with each drug present in the solution. This means that the assay cannot 
distinguish between the two drugs and give a reliable calculation of the amount of either 
drug present (Feldkamp, 2010). 
Of the two commonly used mass spectrometry methods, LC-MS/MS offers several 
advantages over GC-MS (Mikel et al., 2010). These include the ability to discriminate a 
larger number of drugs in each test run, the very small amount of urine specimen required 
(as little as 25 microliters, or one drop), and the ability to use a sample that is neither 
derivatized nor extracted. This in turn has made possible the analysis of hundreds of urine 
specimens per day for a single mass spectrometer. Advances in the automated handling of 
specimens and bar coding allow for the accurate processing of thousands of samples per 
day. This method of analysis can provide physicians with results more rapidly than by GC-
MS (Mikel et al., 2010). 
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4. Interpretation of UDT results 
The accurate interpretation of test results requires an understanding of the usefulness and 
limitations of immunoassays (Gourlay et al., 2010; Hammett-Stabler & Webster, 2008; 
Manchikanti et al., 2010; Nafziger & Bertino, 2009; Reisfield et al., 2007), a knowledge of opiate 
metabolism, and awareness of the expected ratios of the parent drug and its metabolites in 
urine (Reisfield et al., 2007). In addition, small amount of impurities in medications detectable 
by mass spectrometry can complicate the interpretation of UDT results. For example, codeine 
is present in morphine preparations and hydrocodone is present in oxycodone preparations 
(Evans et al., 2009; West et al., 2009, 2011b). Physicians who aren’t aware of the presence of 
these impurities may wrongly dismiss a patient because he or she tested positive for codeine 
or hydrocodone when it was not prescribed.  The presence of both parent drug and its 
metabolite in a urine sample readily measured by mass spectrometry can reassure the 
physician that the patient is taking the medication and that it is being metabolized 
appropriately. Also, for some drugs such as carisoprodol, fentanyl, or buprenorphine, only the 
metabolite may be observed. It is imperative that physicians prescribing these medications use 
a reference laboratory that is able to measure both the parent drug and its corresponding 
metabolite and be able to present interpretive results for the physician (Heltsley et al., 2010). 
Creatinine is a metabolic breakdown product that is present in urine. The amount of 
creatinine excreted into urine is nearly constant for any individual. Reference laboratories 
calculate the amount of drug excreted per gram of creatinine, which allows the monitoring 
of excreted medication or illicit drug over time. This information is useful to physicians in 
certain circumstances because some drugs, such as nordiazepam remain in the system long 
after a person stops taking them. A UDT result that is not corrected for creatinine may show 
that the patient is more positive for the drug than on a previous test, even though the 
patient has in fact stopped taking it. Except for changes in the patient’s renal status, or loss 
from adipose tissue due to dieting, this conflicting result may be due to the second urine 
being more concentrated than the first. A creatinine-corrected value will correct for a 
patient’s hydration on the day of the test and show a decrease in the amount of 
nordiazepam in the urine, thus supporting the patient’s claim that he or she has stopped 
taking the drug. It is important that reference laboratories not only provide creatinine-
corrected results but that they give doctors or staff help in interpreting the data (Cone et al., 
2009). It is also important for the physician to know if a patient has attempted to obscure 
UDT results by diluting a urine specimen. To accomplish this, he or she must have a grasp 
of creatinine and specific gravity UDT validity tests (Wu, 2001). Laboratory staff who 
interface with clients should provide this information when questions arise. 
5. Monitoring ethanol use in pain patients 
As stated earlier, alcohol (ethanol) use among pain patients is a significant problem because 
of the risk for drug-drug interaction with opioid medication. For doctors to understand UDT 
ethanol results, it is essential that they understand ethanol metabolism and the formation of 
the ethanol byproducts ethyl glucuronide and ethyl sulfate (Crews et al., 2011a; Crews et al., 
2011b; Dahl et al., 2002; Helander & Beck, 2005; Helander et al., 1996; Rosano & Lin, 2008; 
Schmitt et al., 1997; Stephanson et al., 2002; Wojcik & Hawthorne, 2007; Wurst et al., 2006; 
Wurst et al., 2004). This is because false positive ethanol results can result from fermentation 
of glucose from diabetic patient samples (Crews et al., 2011b). Crews et al. reported that 
about 1/3 of the ethanol positive samples were due to fermentation. Misinterpretation of 
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these results can have grave consequences as doctors may establish a contract with a patient 
that he or she abstain from any alcohol use while being treated with opioid medication; 
therefore, a positive finding for alcohol use can result in dismissal from the practice (Federal 
Register, 2004).  
6. When to use UDT 
Urine drug testing must be tailored to fit the pain patient’s clinical history. For the intake visit, 
the patient is advised as to the necessity for UDT and is typically requested to provide a urine 
specimen. If the patient fails to do this, he or she may be immediately dismissed from the 
practice. In some practices, the urine specimen is tested by a POC device at the time of the 
appointment and the results are compared to the patient reported history.   If necessary, 
discrepancies are discussed. As a matter of course, a portion of the POC urine sample is sent to 
the reference laboratory to confirm the POC test results, test for additional medications, and, at 
the discretion of the physician, to test for the prescribed medications, non-prescribed 
medications  and  illicit drugs at lower cutoff levels than those provided by the POC test.  
For many established pain patients, quarterly or semi-annual UDT is considered 
appropriate. It is best if this is done on a random basis. The strongest recommendation for 
doing UDT is adding additional medications to the regimen or changing medications. Urine 
drug testing may also be administered if a patient changes their behavior or exhibits 
addiction tendencies such as complaining of running out of medications early (Chou et al., 
2009; Trescot et al., 2006). Testing may be conducted as frequently as every office visit for 
some patients who exhibit unusual behavior, have a history of abuse, or if illicit or non-
prescription drugs were found to be present on a previous test. Gourlay, D. & Heit, H. 
(2010a). 
7. Purposes and costs of UDT 
As stated earlier, the purpose of UDT (as well as the relative costs) may be broken down 
into three components: testing prescribed medications for compliance; testing for non-
prescribed medications; and testing for illicit drugs. At the time when the forensic model of 
drug testing was instituted the vast majority of people who died from drugs died from the 
use of illicit drugs. At this point in time more people die from prescription medications than 
by illicit drugs (Hall et al., 2008; Krausz et al., 1996; Okie, 2010). There are now 13 or more 
classes of drugs that are used to treat pain. Pain patients are on an average using three of 
these drugs (Kuehn, 2007; Okie, 2010). Therefore, for every 100 patients, 300 confirmations 
by mass spectroscopy are required. This is more than a 100-fold increase in the number of 
tests needed to serve this patient population compared to workplace testing. This represents 
a radical change in UDT model from the forensic model used at the time when the purpose 
of drug testing was to root out the one or two percent of drug-using professional drivers. It 
is important that legislators and payors for UDT services understand the shift from the 
forensic UDT model to the clinical model. Currently the insurance reimbursement codes and 
categories do not accurately reflect the costs associated with these new clinical drug testing 
requirements (Cpt Current Procedural Technology, 2010). 
7.1 Cost effectiveness of UDT 
It is also important to discuss the cost-effectiveness of UDT. The National Institute on Drug 
Abuse (NIDA) states that the cost of not treating an addict is $56,000/year. An example of 
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effective treatment for heroin addiction is the methadone maintenance program, which has an 
average cost of $4,700/per patient/per year (Principles of Drug Addiction Treatment: A 
Research-Based Guide, 2009). Based on these figures, every dollar invested in drug treatment 
programs yields a return of about 12 times this amount. The goal then should be detecting 
untreated drug abuse. Urine drug testing helps accomplish this goal.  
There are two aspects of drug abuse in the pain patient population; one is the use of illicit 
drugs, and the other more prevalent aspect is abuse of the prescribed and non-prescribed 
medications. Combined, these two facets of abuse may approach 20-30% of the patients on 
chronic opioid therapy. Using this percentage of patients and factoring the $56,000/patient 
cost, this means that on average each of these patients may actually be costing society and 
insurers $16,800 more annually than what is estimated by only calculating costs of office visits 
and medications. If clinical UDT is performed 2-4 times per year for each patient reimbursed at 
$500 per UDT, this represents a cost of $1000-$2000 per patient per year. This is in contrast to 
the $16,800 referenced above. It seems clear that using UDT to detect these patients should 
significantly reduce the cost of care as well as the costs to society (Wall et al., 2000). 
7.2 Social costs of drug abuse 
In light of the fact that providing the highest standard of care is one of the basic tenets of the 
medical profession, it is important to note that several studies have shown that untreated 
opioid-abusing patients have significantly higher societal cost (Wall et al., 2000) and 
mortality rate (between 2 and 10 times) than the comparative general population (Hall et al., 
2008; Oyefeso et al., 1999). Based on this data alone, the use of UDT should be justified for 
pain patients.  
8. Conclusions 
8.1 When and how to test 
Pain is a complex disease and chronic opioid therapy is one of the treatments of choice. 
Urine drug testing is one of the ways to measure patient adherence to the treatment 
regimen. At the intake office visit it is important for the physician to be able to make 
immediate assessment of the patient to validate their reported history and to determine the 
overt presence of illicit drugs or non-prescribed medications. Either a POC device or in-
office immunoassay analyzer should be used for this purpose. A portion of the patient’s 
urine specimen should be sent to a reference laboratory for analysis using lower cutoffs and 
a much extended test menu such as those listed in Tables 1 and 2. As stated earlier, this will 
give the physician further confidence that the patient’s history is valid and provide 
measurable evidence for informed clinical decision making. In addition, alcohol use, which 
cannot easily be detected by the POC devices, can be identified as a risk factor.  
8.2 Ongoing testing 
At subsequent visits UDT will provide the physician with evidence of patient compliance 
with prescribed medications (West et al., 2010a) and eliminate the potential for abuse of 
non-prescribed medications or illicit drugs (Pesce et al., 2010b). For this purpose,  depending 
upon clinical judgment, the test menu does not have to be quite as extensive. Tests for 
rarely-observed illicit drugs such as MDMA and PCP may not be included. Similarly, tests 
for rarely-prescribed or removed medications such as propoxyphene may not be included. If 
intake visit UDT showed that the patient was observed to be taking a non-prescribed 
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medication or illicit drug then subsequent visit UDT’s should include tests for those agents. 
Because of the potential for morbidity from alcohol-medication interactions, it may be 
necessary to continue to monitor certain patients for ethanol and its metabolites.  
8.3 Minimum analytical requirements 
When monitoring for opioid medication compliance, the testing method should be able to 
differentiate between codeine, morphine, hydrocodone, norhydrocodone, and 
hydromorphone. The test should also be able to differentiate between oxycodone, 
noroxycodone, and oxymorphone. This will allow the physician to determine that the opiate 
the patient is taking is in fact the one being prescribed and that the patient is metabolizing 
the medication properly (Pesce et al., 2010a). A similar case can be made for the testing of 
benzodiazepines. The method should be able to detect at low concentrations and 
differentiate between alpha-hydroxyalprazolam, 7-aminoclonazepam, lorazepam, 
nordiazepam, temazepam, and oxazepam. This will allow the doctor to see that the patient 
is taking the prescribed benzodiazepine and allay any concerns about doctor shopping. 
Frequency of UDT should be based on the physician’s observations of the patient’s behavior 
as well as suggested guidelines. For those patients whose behavior is not of concern, some 
guidelines suggest UDT between two and four times per year on a random basis (Chou et 
al., 2009; Trescot et al., 2006). For those patients with non-compliant behavior or a history of 
addiction, testing should be done as often as every office visit (Chou et al., 2009; Trescot et 
al., 2006). 
9. References 
Agilent Technologies, Inc. 5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA. Thermo 
Fisher Scientific. 81 Wyman St, Waltham, MA 02454, USA. 
Amedica Drug Screen Test Cup. Hayward, CA: Amedica Biotech, Inc. 
American Proficiency Institute 2011 Catalog of Programs. Traverse City, MI: American 
Proficiency Institute, 2011. 
Atluri, S. & Sudarshan, G. (2003). Evaluation of Abnormal Urine Drug Screens among 
Patients with Chronic Non-Malignant Pain Treated with Opioids. Pain Physician, 
Vol.6, No.4, pp.407-409,  
Chou, R., Fanciullo, G., Fine, P., Adler, J., Ballantyne, J., Davies, P., Donovan, M., Fishbain, 
D., Foley, K., Fudin, J., Gilson, A., Kelter, A., Mauskop, A., O’Connor, P., Passik, S., 
Pasternak, G., Portenoy, R., Rich, B., Roberts, R., Todd, K. & Miaskowski, C. (2009). 
Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer 
Pain. The Journal of Pain, Vol.10, No.2, (February 2009), pp.113-130, 1526-5900 
College of American Pathologists 2011 Surveys and Anatomic Pathology Education 
Programs. Northfield, IL: College of American Pathologists, 2011. 
Cone, E., Caplan, Y., Black, D., Robert, T. & Moser, F. (2008). Urine Drug Testing of Chronic 
Pain Patients: Licit and Illicit Drug Patterns. Journal of Analytical Toxicology, Vol.32, 
No.8, (October 2008), pp.530-543, ISSN 1945-2403 
Cone, E., Caplan, Y., Moser, F., Robert, T., Shelby, M. & Black, D. (2009). Normalization of 
Urinary Drug Concentrations with Specific Gravity and Creatinine. Journal of 
Analytical Toxicology, Vol.33, No.1, (January-February 2009), pp.1-7, ISSN 1945-2403 
www.intechopen.com
Diagnostic Accuracy and Interpretation 
of Urine Drug Testing for Pain Patients: An Evidence-Based Approach 
 
41 
Cpt Current Procedural Technology. (2010). ( Professional ed.),  American Medical Association, 
Chicago, IL 
Crews, B., Latyshev, S., Mikel, C., Almazan, P., West, R., Pesce, A. & West, C. (2011a). 
Improved Detection of Ethyl Glucuronide and Ethyl Sulfate in a Pain Management 
Population Using High-Throughput Lc-Ms/Ms. Journal of Opioid Management, 
Vol.6, No.6, (Novenber-December 2010), pp.415-421, ISSN 1551-7489 
Crews, B., West, R., Gutierrez, R., Latyshev, S., Mikel, C., Almazan, P., Pesce, A., West, C. & 
Rosenthal, M. (2011b). An Improved Method of Determining Ethanol Use in a 
Chronic Pain Population. Journal of Opioid Management, Vol.In Press, (n.d.), ISSN 
1551-7489 
Dahl, H., Stephanson, N., Beck, O. & Helander, A. (2002). Comparison of Urinary Excretion 
Characteristics of Ethanol and Ethyl Glucuronide. Journal of Analytical Toxicology, 
Vol.26, No.4, (May-June 2002), pp.201-204, ISSN 1945-2403 
Evans, M., Kriger, S., Gunn, J. & Schwilke, E. (2009). Anomalous Opiate Detection in 
Compliance Monitoring. Practical Pain Management, Vol.9, No.7, (September 2009), 
pp.54-55,  
Federal Register - Mandatory Guidelines and Proposed Revisions to Mandatory Guidelines 
for Federal Workplace Drug Testing Programs. Substance Abuse and Mental 
Health Services Administration. Rockville, MD: Department of Health and Human 
Services, 2004;69(71). 
Feldkamp, C.S. (2010). Immunological Reactions, In: Clinical Chemistry: Theory, Analysis, and 
Correlation, L. A. Kaplan and A. J. Pesce, pp. 151-179, Mosby, St. Louis 
Fraser, A. & Zamecnik, J. (2003). Impact of Lowering the Screening and Confirmation Cutoff 
Values for Urine Drug Testing Based on Dilution Indicators. Therapeutic Drug 
Monitoring, Vol.25, No.6, (December 2003), pp.723-727, ISSN 1536-3694 
Fraser, A.D. (2001). Psychotropic Agents: The Benzodiazepines, In: The Clinical Toxicology 
Laboratory: Contemporary Practice of Poisoning Evaluation, L. C. Shaw, T. C. Kwong, T. 
G. Rosano, P. J. Orsolak, B. A. Wolf and B. Magnani, pp. 211-221, American 
Association for Clinical Chemistry, Inc., Washington, DC 
Gourlay, D. & Heit, H. (2010a). The Art and Science of Urine Drug Testing. The Clinical 
Journal of Pain, Vol.26, No.4, (May 2010), pp.358, ISSN 0749-8047 
Gourlay, D., Heit, H. & Almahrezi, A. (2005). Universal Precautions in Pain Medicine: A 
Rational Approach to the Treatment of Chronic Pain. Pain Medicine, Vol.6, No.2, 
(March-April 2010), pp.107-112, ISSN 1526-4637 
Gourlay, D., Heit, H. & Caplan, Y. Urine Drug Testing in Clinical Practice: The Art and 
Science of Patient Care. California Academy of Family Physicians. Stamford, CT: 
PharmaCom Group, Inc., 2010. 
Gourlay, D. & Heit, H.A. (2010b). The Art and Science of Urine Drug Testing. Clin J Pain, 
Vol.26, No.4, pp.358,  
Hall, A., Logan, J., Toblin, R., Kaplan, J., Kraner, J., Bixler, D., Crosby, A. & Paulozzi, L. 
(2008). Patterns of Abuse among Unintentional Pharmaceutical Overdose Fatalities. 
JAMA, Vol.300, No.22, (December 2008), pp.2613-2620, ISSN 1538-3598 
Hammett-Stabler, C. & Webster, L. A Clinical Guide to Urine Drug Testing: Augmenting 
Pain Management and Enhancing Patient Care. University of Medicine and 
www.intechopen.com
 
Toxicity and Drug Testing 
 
42
Dentistry of New Jersay - Center for Continuing and Outreach Education. 
Stamford, CT: PharmaCom Group, Inc, 2008. 
Harmful Interactions: Mixing Alcohol with Medicines. National Institute on Alcohol Abuse 
and Alcoholism. Bethesda, MD: National Institutes of Health, 2007. 
Hattab, E., Goldberger, B., Johannsen, L., Kindland, P., Ticino, F., Chronister, C. & Bertholf, 
R. (2000). Modification of Screening Immunoassays to Detect Sub-Threshold 
Concentrations of Cocaine, Cannabinoids, and Opiates in Urine: Use for Detecting 
Maternal and Neonatal Drug Exposures. Annals of Clinical and Laboratory Science, 
Vol.31, No.1, (January 2000), pp.85-91, ISSN 1550-8080 
Helander, A. & Beck, O. (2005). Ethyl Sulfate: A Metabolite of Ethanol in Humans and a 
Potential Biomarker of Acute Alcohol Intake. Journal of Analytical Toxicology, Vol.29, 
No.5, (July-August 2005), pp.270-274, ISSN 1945-2403 
Helander, A., Beck, O. & Jones, A. (1996). Laboratory Testing for Recent Alcohol 
Consumption: Comparison of Ethanol, Methanol, and 5-Hydroxytryptophol. 
Clinical Chemistry, Vol.42, No.4, (April 1996), pp.618-624, ISSN 1530-8561 
Heltsley, R., Zichterman, A., Black, D., Cawthon, B., Robert, T., Moser, F., Caplan, Y. & 
Cone, E. (2010). Urine Drug Testing of Chronic Pain Patients. Ii. Prevalence Patterns 
of Prescription Opiates and Metabolites. Journal of Analytical Toxicology, Vol.34, 
No.1, (January-February 2010), pp.32-38, ISSN 1945-2403 
Ives, T., Chelminski, P., Hammett-Stabler, C., Malone, R., Perhac, J., Potisek, N., Shilliday, B., 
DeWalt, D. & Pignone, M. (2006). Predictors of Opioid Misuse in Patients with 
Chronic Pain: A Prospective Cohort Study. BMC Health Services Research, Vol.6, 
No.1, (April 2006), pp.46, ISSN 1472-6963 
Jung, B. & Reidenberg, M. (2007). Physicians Being Deceived. Pain Medicine, Vol.8, No.5, 
(July-August 2007), pp.433-437, ISSN 1526-4637 
Katz, N., Sherburne, S., Beach, M., Rose, R., Vielguth, J., Bradley, J. & Fanciullo, G. (2003). 
Behavioral Monitoring and Urine Toxicology Testing in Patients Receiving Long-
Term Opioid Therapy. Anesthesia and Analgesia, Vol.97, No.4, (October 2003), 
pp.1097-1102, ISSN 1526-7598 
Krausz, M., Degkwit, P., Haasen, C. & Verthein, U. (1996). Opioid Addiction and Suicidality. 
Crisis, Vol.17, No.4, pp.175-181,  
Kuehn, B.M. (2007). Opioid Prescriptions Soar: Increase in Legitimate Use as Well as Abuse. 
JAMA, Vol.297, No.3, pp.249-251, 0098-7484 1538-3598 
Madras, B., Compton, W., Avula, D., Stegbauer, T., Stein, J. & Clark, H. (2009). Screening, 
Brief Interventions, Referral to Treatment (Sbirt) for Illicit Drug and Alcohol Use at 
Multiple Healthcare Sites: Comparison at Intake and 6 Months Later. Drug and 
Alcohol Dependence, Vol.99, No.1-3, (January 2009), pp.280-295, ISSN 1879-0046 
Manchikanti, L., Atluri, S., Trescot, A. & Giordano, J. (2008). Monitoring Opioid Adherence 
in Chronic Pain Patients: Tools, Techniques, and Utility. Pain Physician, Vol.11, 
No.2, (March 2008), pp.S155-S180, ISSN 1533-3159 
Manchikanti, L., Cash, K., Damron, K., Manchukonda, R., Pampati, V. & McManus, C. 
(2006a). Controlled Substance Abuse and Illicit Drug Use in Chronic Pain Patients: 
An Evaluation of Multiple Variables. Pain Physician, Vol.9, No.3, (July 2006), 
pp.215-226, ISSN 1533-3159 
www.intechopen.com
Diagnostic Accuracy and Interpretation 
of Urine Drug Testing for Pain Patients: An Evidence-Based Approach 
 
43 
Manchikanti, L., Damron, K., McManus, C. & Barnhill, R. (2004). Patterns of Illicit Drug Use 
and Opioid Abuse in Patients with Chronic Pain at Initial Evaluation: A 
Prospective, Observational Study. Pain Physician, Vol.7, No.4, (October 2004), 
pp.431-437, ISSN 1533-3159 
Manchikanti, L., Malla, Y., Wargo, B., Cash, K., Pampati, V., Damron, K., McManus, C. & 
Brandon, D. (2010). Protocol for Accuracy of Point of Care (Poc) or in-Office Urine 
Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of 
Immunoassay and Liquid Chromatography Tandem Mass Spectometry 
(Lc/Ms/Ms). Pain Physician, Vol.13, No.1, (January 2010), pp.E1-E22, ISSN 1533-
3159 
Manchikanti, L., Manchukonda, R., Pampati, V., Damron, K., Brandon, D., Cash, K. & 
McManus, C. (2006b). Does Random Urine Drug Testing Reduce Illicit Drug Use in 
Chronic Pain Patients Receiving Opioids? Pain Physician, Vol.9, No.2, (April 2006), 
pp.123-129, ISSN 1533-3159 
Manchikanti, L., Manchukonda, R., Pampati, V. & Damron, K.S. (2005). Evaluation of Abuse 
of Prescription and Illicit Drugs in Chronic Pain Patients Receiving Short-Acting 
(Hydrocodone) or Long-Acting (Methadone) Opioids. Pain Physician, Vol.8, No.3, 
pp.257-261,  
Michna, E., Jamison, R., Pham, L., Ross, E., Janfaza, D., Nedeljkovic, S., Narang, S., Palombi, 
D. & Wasan, A. (2007). Urine Toxicology Screening among Chronic Pain Patients on 
Opioid Therapy: Frequency and Predictability of Abnormal Findings. The Clinical 
Journal of Pain, Vol.23, No.2, (February 2007), pp.173-179, ISSN 1536-5409 
Mikel, C., Almazan, P., West, R., Crews, B., Latyshev, S., Pesce, A. & West, C. (2009). Lc-
Ms/Ms Extends the Range of Drug Analysis in Pain Patients. Therapeutic Drug 
Monitoring, Vol.31, No.6, (December 2009), pp.746-748, ISSN 1536-3694 
Mikel, C., Pesce, A. & West, C. (2010). A Tale of Two Drug Testing Technologies: Gc-Ms and 
Lc-Ms/Ms. Pain Physician, Vol.13, No.1, pp.91-92,  
Mohsin, S., Yang, Y. & Zumwalt, M. Quantitative Analysis of Opiates in Urine Using Rrht 
Lc/Ms/Ms. Santa Clara, CA: Agilent Technologies, Inc., 2007. 
Nafziger, A. & Bertino, J., Jr. (2009). Utility and Application of Urine Drug Testing in 
Chronic Pain Management with Opioids. The Clinical Journal of Pain, Vol.25, No.1, 
(January 2009), pp.73-79, ISSN 1536-5409 
National Prescription Drug Threat Assesment. U.S. Department of Justice. Johnstown, PA: 
National Drug Intelligence Center, 2009. 
National Survey on Drug Use and Health: Detailed Tables - Prevalence Estimates, Standard 
Errors, P Values, and Sample Sizes. Substance Abuse and Mental Health Services 
Administration. Rockville, MD: Department of Health and Human Services, 1995-
2006. 
Nucynta - Tapentadol. (2010). December 3, 2010, Available from: <www.nucynta.com> 
Okie, S. (2010). A Flood of Opioids, a Rising Tide of Deaths. The New England Journal of 
Medicine, Vol.363, No.21, (November 2010), pp.1981-1985, ISSN 1533-4406 
Olympus Au640 Product Information. Brea, CA: Beckman Coulter, Inc. Lab Systems and 
Routine Testing. 
www.intechopen.com
 
Toxicity and Drug Testing 
 
44
Oyefeso, A., Ghodse, H., Clancy, C., Corkery, J. & Goldfinch, R. (1999). Drug Abuse-Related 
Mortality: A Study of Teenage Addicts over a 20-Year Period. Social Psychiatry and 
Psychiatric Epidemiology, Vol.34, No.8, (August 1999), pp.437-441, ISSN 1433-9285 
Pesce, A., Rosenthal, M., West, R., West, C., Crews, B., Mikel, C., Almazan, P. & Latyshev, S. 
(2010a). An Evaluation of the Diagnostic Accuracy of Liquid Chromatography-
Tandem Mass Spectrometry Versus Immunoassay Drug Testing in Pain Patients. 
Pain Physician, Vol.13, No.3, pp.273-281,  
Pesce, A., West, C., Rosenthal, M., West, R., Crews, B., Mikel, C., Almazan, P., Latyshev, S. & 
Horn, P. (2010b). Marijuana Correlates with Use of Other Illicit Drugs in a Pain 
Patient Population. Pain Physician, Vol.13, No.3, pp.283-287,  
Pesce, A., West, C., West, R., Crews, B., Mikel, C., Almazan, P., Latyshev, S., Rosenthal, M. & 
Horn, P. (2010c). Reference Intervals: A Novel Approach to Detect Drug Abuse in a 
Pain Patient Population. Journal of Opioid Management, Vol.6, No.5, (September-
October 2010), pp.341-350, ISSN 1551-7489 
Pesce, A., West, C., West, R., Crews, B., Mikel, C., Rosenthal, M., Almazan, P. & Latyshev, S. 
(2011). Determination of Medication Cutoff Values in a Pain Patient Population. 
Journal of Opioid Management, Vol.In Press, (n.d.), ISSN 1551-7489 
Principles of Drug Addiction Treatment: A Research-Based Guide. National Institue on 
Drug Abuse. Bethesda, MD: Department of Health and Human Services, 2009. 
Reisfield, G., Salazar, E. & Bertholf, R. (2007). Rational Use and Interpretation of Urine Drug 
Testing in Chronic Opioid Therapy. Annals of Clinical and Laboratory Science, Vol.37, 
No.4, (Autumn 2007), pp.301-314, ISSN 1550-8080 
Rosano, T. & Lin, J. (2008). Ethyl Glucuronide Excretion in Humans Following Oral 
Administration of and Dermal Exposure to Ethanol. Journal of Analytical Toxicology, 
Vol.32, No.8, (October 2008), pp.594-600, ISSN 1945-2403 
Schmitt, G., Droenner, P., Skopp, G. & Aderjan, R. (1997). Ethyl Glucuronide Concentration 
in Serum of Human Volunteers, Teetotalers, and Suspected Drinking Drivers. 
Journal of Forensic Sciences, Vol.42, No.6, (November 1997), pp.1099-1102, ISSN 1556-
4029 
Schuckman, H., Hazelett, S., Powell, C. & Steer, S. (2008). A Validation of Self-Reported 
Substance Use with Biochemical Testing among Patients Presenting to the 
Emergency Department Seeking Treatment for Backache, Headache, and 
Toothache. Substance Use and Misuse, Vol.43, No.5, (n.d.), pp.589-595, ISSN 1433-
9285 
Siemens V-Twin Analyzer Product Information. Hermosa Beach, CA: Siemens Healthcare 
Diagnostic, Inc. 
Siuzdak, G. (2006). The Expanding Role of Mass Spectrometry in Biotechnology (2nd ed.),  MCC 
Press, San Diego, CA 
Sobolevsky, T., Prasolov, I. & Rodchenkov, G. (2010). Detection of Jwh-018 Metabolites in 
Smoking Mixture Post-Administration Urine. Forensic Science International, Vol.200, 
No.1-3, (July 2010), pp.141-147, ISSN 1872-6283 
Stephanson, N., Dahl, H., A., H. & Beck, O. (2002). Direct Quantification of Ethyl 
Glucuronide in Clinical Urine Samples by Liquid Chromatography-Mass 
www.intechopen.com
Diagnostic Accuracy and Interpretation 
of Urine Drug Testing for Pain Patients: An Evidence-Based Approach 
 
45 
Spectrometry. Therapeutic Drug Monitoring, Vol.24, No.5, (October 2002), pp.645-
651, ISSN 1536-3694 
Thermo Fisher Mgc-240 Analyzer Product Information. Franklin, MA: Thermo Fisher 
Scientific. 
Trescot, A., Boswell, M., Atluri, S., Hansen, H., Deer, T., Abdi, S., Jasper, J., Singh, V., Jordan, 
A., Johnson, B., Cicala, R., Dunbar, E., Helm, S., II, Varley, K., Suchdev, P., 
Swicegood, J., Calodney, A., Ogoke, B., Minore, W. & Manchikanti, L. (2006). 
Opioid Guidelines in the Management of Chronic Non-Cancer Pain. Pain Physician, 
Vol.9, No.1, (January 2006), pp.1-40, ISSN 1533-3159 
Vardakou, I., Pistos, C. & Spiliopoulou, C. (2010). Spice Drugs as a New Trend: Mode of 
Action, Identification and Legislation. Toxicology Letters, Vol.197, No.3, (September 
2010), pp.157-162, ISSN 1879-3169 
Wall, R., Rehm, J., Fischer, B., Brands, B., Gliksman, L., Stewart, J., Medved, W. & Blake, J. 
(2000). Social Costs of Untreated Opioid Dependence. Journal of Urban Health, 
Vol.77, No.4, (December 2000), pp.688-722, ISSN 1468-2869 
Webster, L. & Dove, B. (2007). Avoiding Opioid Abuse While Managing Pain: A Guide for 
Practitioners,  Sunrise River Press, North Branch, MN 
West, R., Crews, B., Mikel, C., Almazan, P., Latyshev, S., Pesce, A. & West, C. (2009). 
Anomalous Observations of Codeine in Patients on Morphine. Therapeutic Drug 
Monitoring, Vol.31, No.6, (December 2009), pp.776-778, ISSN 1536-3694 
West, R., Pesce, A., Crews, B., Mikel, C., Rosenthal, M., Almazan, P., Latyshev, S. & West, C. 
(2011a). Determination of Illicit Drug Cutoff Values in a Pain Patient Population. 
Clinica Chimica Acta, Vol.In Press, (n.d.), ISSN 1873-3492 
West, R., Pesce, A., Mikel, C., Rosenthal, M., Latyshev, S., Crews, B. & Almazan, P. (2010a). 
Observations of Medication Compliance by Measurement of Urinary Drug 
Concentrations in a Pain Management Population. Journal of Opioid Management, 
Vol.6, No.4, (July-August 2010), pp.253-257, ISSN 1551-7489 
West, R., Pesce, A., West, C., Crews, B., Mikel, C., Almazan, P., Rosenthal, M. & Latyshev, S. 
(2010b). Comparison of Clonazepam Compliance by Measurement of Urinary 
Concentration by Immunoassay and Lc-Ms/Ms in Pain Management Population. 
Pain Physician, Vol.13, No.1, pp.71-78,  
West, R., West, C., Crews, B., Almazan, P., Latyshev, S., Rosenthal, M., Pesce, A. & Mikel, C. 
(2011b). Anomalous Observations of Hydrocodone in Patients on Oxycodone. 
Clinica Chimica Acta, Vol.412, No.1-2, (January 2011), pp.29-32, ISSN 1873-3492 
Wingert, W. (1997). Lowering Cutoffs for Initial and Confirmation Testing for Cocaine and 
Marijuana: Large-Scale Study of Effects on the Rates of Drug-Positive Results. 
Clinical Chemistry, Vol.43, No.1, (January 1997), pp.100-103, ISSN 1530-8561 
Wojcik, M. & Hawthorne, J. (2007). Sensitivity of Commercial Ethyl Glucuronide (Etg) 
Testing in Screening for Alcohol Abstinence. Alcohol and Alcoholism, Vol.42, No.4, 
(July-August 2007), pp.317-320, ISSN 1464-3502 
Wu, A.H.B. (2001). Urine Adulteration before Testing for Drugs of Abuse, In: The Clinical 
Toxicology Laboratory: Contemporary Practice of Poisoning Evaluation, L. C. Shaw, T. C. 
Kwong, T. G. Rosano, P. J. Orsolak, B. A. Wolf and B. Magnani, pp. 157-171, 
American Association for Clinical Chemistry, Inc., Washington, DC 
www.intechopen.com
 
Toxicity and Drug Testing 
 
46
Wurst, F., Dresen, S., Allen, J., Wiesbeck, G., Graf, M. & Weinmann, W. (2006). Ethyl 
Sulphate: A Direct Ethanol Metabolite Reflecting Recent Alcohol Consumption. 
Addiction, Vol.101, No.2, (February 2006), pp.204-211, ISSN 1360-0443 
Wurst, F., Wiesbeck, G., Metzger, J., Weinmann, W. & Graf, M. (2004). On Sensitivity, 
Specificity, and the Influence of Various Parameters on Ethyl Glucuronide Levels in 
Urine - Results from the Who/Isbra Study. Alcoholism, Clinical and Experimental 
Research, Vol.28, No.8, (August 2004), pp.1220-1228, ISSN 1530-0277 
 
www.intechopen.com
Toxicity and Drug Testing
Edited by Prof. Bill Acree
ISBN 978-953-51-0004-1
Hard cover, 528 pages
Publisher InTech
Published online 10, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Modern drug design and testing involves experimental in vivo and in vitro measurement of the drug
candidate's ADMET (adsorption, distribution, metabolism, elimination and toxicity) properties in the early
stages of drug discovery. Only a small percentage of the proposed drug candidates receive government
approval and reach the market place. Unfavorable pharmacokinetic properties, poor bioavailability and
efficacy, low solubility, adverse side effects and toxicity concerns account for many of the drug failures
encountered in the pharmaceutical industry. Authors from several countries have contributed chapters
detailing regulatory policies, pharmaceutical concerns and clinical practices in their respective countries with
the expectation that the open exchange of scientific results and ideas presented in this book will lead to
improved pharmaceutical products.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Amadeo Pesce, Cameron West, Kathy Egan-City and William Clarke (2012). Diagnostic Accuracy and
Interpretation of Urine Drug Testing for Pain Patients: An Evidence-Based Approach, Toxicity and Drug
Testing, Prof. Bill Acree (Ed.), ISBN: 978-953-51-0004-1, InTech, Available from:
http://www.intechopen.com/books/toxicity-and-drug-testing/urine-drug-testing-in-pain-patients
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
